Bayer: new positive data for elinzanetant

(CercleFinance.com) - Bayer announced on Thursday positive Phase III data for elinzanetant in the treatment of vasomotor disorders caused by breast cancer therapies.


The German pharmaceutical group, which specializes in women's health, reports that its drug successfully met its primary endpoints by significantly reducing the frequency of hot flushes compared with placebo after four and 12 weeks.

The study also met its secondary endpoints by reducing the severity of symptoms, again after four and 12 weeks of treatment.

Bayer points out that elinzanetant also reduced sleep disturbances and menopause-related problems over a 12-week period compared with placebo.

These symptoms, frequently encountered by people undergoing hormone therapy for breast cancer, often penalize treatment compliance.

Elinzanetant, a dual antagonist of the neurokinin-1 and neurokinin-3 receptors, modulates a group of estrogen-sensitive neurons in the brain's hypothalamus that lead to hyperactivation of the thermoregulatory system and disrupt body heat regulation mechanisms.

Copyright (c) 2025 CercleFinance.com. All rights reserved.